ADC Therapeutics SA (ADCT)
undefined
undefined%
At close: undefined
1.88
0.53%
After-hours Dec 13, 2024, 07:50 PM EST

ADC Therapeutics SA Statistics

Share Statistics

ADC Therapeutics SA has 96.69M shares outstanding. The number of shares has increased by 19.9% in one year.

Shares Outstanding 96.69M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.48%
Owned by Institutions (%) n/a
Shares Floating 77.83M
Failed to Deliver (FTD) Shares 883
FTD / Avg. Volume 0.12%

Short Selling Information

The latest short interest is 3.17M, so 3.28% of the outstanding shares have been sold short.

Short Interest 3.17M
Short % of Shares Out 3.28%
Short % of Float 4.07%
Short Ratio (days to cover) 9.62

Valuation Ratios

The PE ratio is -0.57 and the forward PE ratio is -1.97.

PE Ratio -0.57
Forward PE -1.97
PS Ratio 1.95
Forward PS 2.2
PB Ratio -0.91
P/FCF Ratio -1.11
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

ADC Therapeutics SA has an Enterprise Value (EV) of -18.58M.

EV / Earnings 0.08
EV / Sales -0.27
EV / EBITDA 0.13
EV / EBIT 0.11
EV / FCF 0.15

Financial Position

The company has a current ratio of 4.97, with a Debt / Equity ratio of -0.77.

Current Ratio 4.97
Quick Ratio 4.73
Debt / Equity -0.77
Total Debt / Capitalization -335.36
Cash Flow / Debt -1.04
Interest Coverage -3.58

Financial Efficiency

Return on equity (ROE) is 1.62% and return on capital (ROIC) is 834.46%.

Return on Equity (ROE) 1.62%
Return on Assets (ROA) -0.68%
Return on Capital (ROIC) 834.46%
Revenue Per Employee 254.79K
Profits Per Employee -879.32K
Employee Count 273
Asset Turnover 0.2
Inventory Turnover 0.16

Taxes

Income Tax 39.11M
Effective Tax Rate -0.2

Stock Price Statistics

The stock price has increased by 17.61% in the last 52 weeks. The beta is 1.6, so ADC Therapeutics SA's price volatility has been higher than the market average.

Beta 1.6
52-Week Price Change 17.61%
50-Day Moving Average 2.74
200-Day Moving Average 3.45
Relative Strength Index (RSI) 42
Average Volume (20 Days) 709.55K

Income Statement

In the last 12 months, ADC Therapeutics SA had revenue of $69.56M and earned -$240.05M in profits. Earnings per share was $-2.94.

Revenue 69.56M
Gross Profit 67.03M
Operating Income -165.99M
Net Income -240.05M
EBITDA -146.76M
EBIT -165.99M
Earnings Per Share (EPS) -2.94
Full Income Statement

Balance Sheet

The company has $278.60M in cash and $124.38M in debt, giving a net cash position of $154.22M.

Cash & Cash Equivalents 278.60M
Total Debt 124.38M
Net Cash 154.22M
Retained Earnings -1.34B
Total Assets 349.08M
Working Capital 265.33M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$118.69M and capital expenditures -$3.22M, giving a free cash flow of -$121.90M.

Operating Cash Flow -118.69M
Capital Expenditures -3.22M
Free Cash Flow -121.90M
FCF Per Share -1.49
Full Cash Flow Statement

Margins

Gross margin is 96.36%, with operating and profit margins of -238.63% and -345.11%.

Gross Margin 96.36%
Operating Margin -238.63%
Pretax Margin -280.94%
Profit Margin -345.11%
EBITDA Margin -210.99%
EBIT Margin -238.63%
FCF Margin -175.25%

Dividends & Yields

ADCT does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -157.22%
FCF Yield -67.42%
Dividend Details

Analyst Forecast

The average price target for ADCT is $8, which is 327.8% higher than the current price. The consensus rating is "Buy".

Price Target $8
Price Target Difference 327.8%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -5.62
Piotroski F-Score 2